FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
Jane P. F. Bai(United States Food and Drug Administration), Hao Zhu(United States Food and Drug Administration), Cynthia J. Musante(University of North Carolina at Chapel Hill), Christina Friedrich(Rosa (United States)), Kunal Naik(United States Food and Drug Administration), Kapil Gadkar(Sea Turtle Conservancy), Mark Rogge(Takeda (United States)), Justin Earp(United States Food and Drug Administration), Brian J. Schmidt(Bristol-Myers Squibb (Germany)), Valeriu Damian(Providence College), Piet H. van der Graaf(Pfizer (United Kingdom)), Rajanikanth Madabushi(United States Food and Drug Administration)
Cited by 38
Related Papers
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models
|Nature Neuroscience|2023|227
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
|Clinical Cancer Research|2014|215
Iterative approach to model identification of biological networks
|BMC Bioinformatics|2005|157